GlassScriptPhysician profile
Robert Ezewuiro
NPI 1134571334
$20,624.08
in general payments reported to CMS, 2019-2025
37 companies · $865 in 2025
The $865 reported for 2025 was more than what 86% of Primary Podiatric Medicine providers received nationally (typical 2025 total: $232).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,635 · 2020: $4,451 · 2021: $5,181 · 2022: $5,120 · 2023: $1,378 · 2024: $995 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,237.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Peerless Surgical INC. | $7,610.80 | 2019-2025 | |
| Arthrex, INC. | $3,543.72 | 2019-2021 | |
| Triad Life Sciences INC. | $1,507.32 | 2022 | |
| Stryker Corporation | $1,409.54 | 2019-2025 | Easyfuse, Ortholoc 3di, Citrefix |
| Treace Medical Concepts, INC. | $1,182.91 | 2021-2025 | |
| Convatec INC. | $1,002.90 | 2023-2025 | |
| Organogenesis INC. | $857.22 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $754.05 | 2021-2022 | |
| Epsfl, LLC | $473.32 | 2023 | |
| Horizon Therapeutics Plc | $325.17 | 2019-2023 | Krystexxa |
| Smith+Nephew, INC. | $291.84 | 2019-2025 | Grafix Pl, Stravix, Oasis |
| Koya Medical, INC. | $193.88 | 2022 | |
| Depuy Synthes Sales INC. | $152.14 | 2022-2025 | Motoband, N/A |
| Acelrx Pharmaceuticals, INC. | $147.02 | 2020 | |
| Amgen INC. | $141.75 | 2024-2025 | Krystexxa |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $130.81 | 2024-2025 | Kerecis Surgiclose, Kerecis Graftguide, Kerecis Omega3 Marigen |
| Nevro Corp. | $129.25 | 2022-2023 | Senza |
| Paratek Pharmaceuticals, INC. | $113.74 | 2023-2025 | Nuzyra |
| Cook Medical LLC | $103.65 | 2019 | |
| Abbott Laboratories | $103.50 | 2023 | Diamondback Peripheral |
| Abbvie INC. | $54.44 | 2023 | |
| Davol INC. | $48.05 | 2025 | Arista |
| Sebela Pharmaceuticals INC. | $46.75 | 2021-2023 | Naftin |
| Baudax Bio INC. | $41.00 | 2020 | |
| Ibsa Pharma INC. | $28.07 | 2023 | Tirosint, Licart |
| Grt US Holding, INC. | $27.53 | 2020 | |
| Stability Biologics, LLC | $27.13 | 2022 | |
| Solventum Corporation | $23.41 | 2025 | Activ.A.C. |
| Averitas Pharma INC. | $23.13 | 2023 | Qutenza |
| Innovation Technologies INC | $19.73 | 2025 | Irrisept |
| Nabriva Therapeutics, Plc | $19.70 | 2021 | |
| Advanced Oxygen Therapy INC. | $18.87 | 2024 | Topical Oxygen Chamber For Extremities |
| Polarityte, INC. | $17.71 | 2019 | |
| Bioventus LLC | $13.81 | 2024 | Exogen Ultrasound Bone Healing System |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.81 | 2021 | |
| Kci USA, INC. | $13.66 | 2020 | |
| Integra Lifesciences Corporation | $12.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ezewuiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.